Multi-center, Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm

Trial Profile

Multi-center, Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Vanoxerine (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Therapeutic Use
  • Acronyms COR-ART
  • Sponsors ChanRx
  • Most Recent Events

    • 17 Nov 2013 Two of the three planned vanoxerine cohorts have been randomised to 200mg (n=22) 300mg (n=25) and placebo (n=22). The third cohort (400mg) is currently being enrolled according to the abstract preseneted at AHA.
    • 17 Nov 2013 Interim results for the 200 and 300mg cohorts presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top